Introduction
============

Due to unfavorable molecular size and lipophilicity, migraine-specific medications such as dihydroergotamine (DHE) are not expected to penetrate the blood-brain barrier (BBB). A breakdown of the BBB during migraine attacks has been postulated as the mechanism in which DHE accesses postulated central sites of action.

Aim
===

To demonstrate whether the permeability of the BBB increases for DHE during migraine attacks.

Methods
=======

As a measure of parenchymal binding in the brain and thus BBB penetration, we calculated the influx rate constant Ki for the radioligand \[11C\]-dihydroergotamine (\[11C\]-DHE) using arterial blood input function over the course of dynamic positron emission tomography (PET). The influence of migraine on the Ki maps, i.e. the BBB was assessed in a second \[11C\]-DHE scan during glyceryl trinitrate (GTN)-induced migraine attacks.

Results
=======

Independent from the presence of migraine headache, six migraineurs and six age- and gender-matched control subjects showed identical binding of \[11C\]-DHE at the choroid plexus, the pituitary gland, and the venous sinuses. There was no binding (Ki = 0/min) in the brain parenchyma, including the candidate brainstem sites of action during migraine (periaqueductal grey, raphe nuclei) and the area with the highest density of the highest-affinity DHE receptors (hippocampus).

Conclusions
===========

The lack of ictal binding of \[11C\]-DHE to the brain parenchyma suggests that the BBB remains intact for DHE during migraine attacks. The efficacy of DHE in treating an acute migraine attack may have a peripheral component although some implicated structures remain outside the BBB.
